Literature DB >> 11571642

p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress.

M Jiang1, T Axe, R Holgate, C P Rubbi, A L Okorokov, T Mee, J Milner.   

Abstract

The tumour suppressor p53 is a multifunctional protein important for the maintenance of genomic integrity. It is able to form molecular complexes with different DNA targets and also with cellular proteins involved in DNA transcription and DNA repair. In mammalian cells the biochemical processing of DNA occurs on a nuclear sub-structure termed the nuclear matrix. Previously Deppert and co-workers have identified p53 in association with the nuclear matrix in viral- and non-viral transformed cell lines. In the present study we demonstrate, for the first time, that p53 is bound to the nuclear matrix in primary cultures of normal mammalian cells and that this binding increases following DNA damage. Analysis of cell lines expressing structural mutants of p53 revealed that association with the nuclear matrix is independent of the tertiary and quaternary structure of p53. However, the proline-rich domain towards the N-terminus of p53 (residues 67 to 98) appeared important for binding to the nuclear matrix. This was demonstrated by TET-ON regulated expression of p53-derived constructs in p53(-/-) murine embryonic fibroblasts (MEF p53(-/-)). The proline-rich domain of p53 has potential for SH3 protein-protein interaction, and has a role in p53-mediated apoptosis and possibly base excision repair of DNA damage. We discuss our observations in relation to the ability of p53 to facilitate DNA repair and also review evidence indicating that matrix-bound p53 in SV40-transformed cells may facilitate the transforming potential of SV40 large T antigen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571642     DOI: 10.1038/sj.onc.1204705

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element.

Authors:  Surajit Sinha; Sunil Kumar Malonia; Smriti P K Mittal; Kamini Singh; Sreenath Kadreppa; Rohan Kamat; Robin Mukhopadhyaya; Jayanta K Pal; Samit Chattopadhyay
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

Review 2.  SH3 domains: modules of protein-protein interactions.

Authors:  Natalya Kurochkina; Udayan Guha
Journal:  Biophys Rev       Date:  2012-06-20

3.  Human Papillomavirus 31 Tyrosine 102 Regulates Interaction with E2 Binding Partners and Episomal Maintenance.

Authors:  Timra Gilson; Sara Culleton; Fang Xie; Marsha DeSmet; Elliot J Androphy
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

4.  Likelihood models of somatic mutation and codon substitution in cancer genes.

Authors:  Ziheng Yang; Simon Ro; Bruce Rannala
Journal:  Genetics       Date:  2003-10       Impact factor: 4.562

5.  Identification and characterization of the product encoded by ORF69 of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Santarelli; A Farina; M Granato; R Gonnella; S Raffa; L Leone; R Bei; A Modesti; L Frati; M R Torrisi; A Faggioni
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

6.  Mutant p53 proteins bind DNA in a DNA structure-selective mode.

Authors:  Thomas Göhler; Stefan Jäger; Gabriele Warnecke; Hideyo Yasuda; Ella Kim; Wolfgang Deppert
Journal:  Nucleic Acids Res       Date:  2005-02-18       Impact factor: 16.971

7.  Actin polymerization negatively regulates p53 function by impairing its nuclear import in response to DNA damage.

Authors:  Ling Wang; Min Wang; Shuyan Wang; Tianyang Qi; Lijing Guo; Jinjiao Li; Wenjing Qi; Khamal Kwesi Ampah; Xueqing Ba; Xianlu Zeng
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

8.  The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor.

Authors:  Jane Lee; Jason Beliakoff; Zijie Sun
Journal:  Nucleic Acids Res       Date:  2007-06-21       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.